Principles of Reporting. (a) The presentation of results of operation of the Parties with respect to Co-Co Products for U.S. Administration will be based on each Party’s respective financial information presented separately and on a consolidated basis in the reporting format depicted as follows: [***] [***] [***] [***] [***] [***] [***] [***] [***]
Appears in 2 contracts
Samples: Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.), Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.)
Principles of Reporting. (a) The presentation of results of operation of the Parties with respect to Co-Co Shared Products for U.S. Administration and Companion Diagnostics will be based on each Party’s respective financial information presented separately and on a consolidated basis in the reporting format depicted as follows: [***] [***] [***] Celgene Vividion Total [***] [***] [***] [***] [***] [***]
Appears in 2 contracts
Samples: License Agreement (Vividion Therapeutics, Inc.), License Agreement (Vividion Therapeutics, Inc.)
Principles of Reporting. (a) The presentation of results of operation of the Parties with respect to Co-Co Shared Products and Companion Diagnostics for U.S. Administration will be based on each Party’s respective financial information presented separately and on a consolidated basis in the reporting format depicted as follows: [***] [***] [***] Celgene Vividion Total [***] [***] [***] [***] [***] [***]
Appears in 2 contracts
Samples: License Agreement (Vividion Therapeutics, Inc.), License Agreement (Vividion Therapeutics, Inc.)
Principles of Reporting. (a) The presentation of results of operation of the Parties with respect to Co-Co Products Product for U.S. Administration will be based on each Party’s respective financial information presented separately and on a consolidated basis in the reporting format depicted as follows: [***] [***] [***] [***] [***] [***] [***] OncoMed Celgene Total [***] [***]
Appears in 1 contract
